- Conditions
- Alzheimer Disease, Early Onset
- Interventions
- AD-35 60mg group, Placebo group
- Drug
- Lead sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 10
- States / cities
- Sacramento, California • San Diego, California • Delray Beach, Florida + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1201–1224
of 33,591
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy
- Interventions
- LY3985297, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Anaheim, California • Salt Lake City, Utah
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
- Interventions
- ASP2138, Pembrolizumab, Oxaliplatin, Leucovorin, Fluorouracil, Ramucirumab, Paclitaxel, Irinotecan, Capecitabine
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 13
- States / cities
- Orange, California • Santa Monica, California • Chicago, Illinois + 8 more
- Conditions
- Multiple Sclerosis
- Interventions
- Polyphenon E
- Drug
- Lead sponsor
- Louisiana State University Health Sciences Center in New Orleans
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Hypertension
- Interventions
- nebivolol, Placebo
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 491 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 75
- States / cities
- Gulf Shores, Alabama • Huntsville, Alabama • Mesa, Arizona + 63 more
- Conditions
- Alzheimer's Disease
- Interventions
- TTP4000, Placebo
- Drug
- Lead sponsor
- vTv Therapeutics
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 3
- States / cities
- Miami, Florida • Durham, North Carolina • High Point, North Carolina
- Conditions
- Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms, Pancreas Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Recurrent, Non-Small Cell Squamous Lung Cancer, NSCLC, NSCLC, Recurrent, Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma, CRC, Colorectal Cancer Metastatic, Cancer
- Interventions
- A2B530, xT-Onco with HLA-LOH Assay
- Biological · Diagnostic Test
- Lead sponsor
- A2 Biotherapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 8
- States / cities
- Gilbert, Arizona • La Jolla, California • Los Angeles, California + 5 more
- Conditions
- Relapsed/Refractory, B-cell Acute Lymphocytic Leukemia
- Interventions
- Blinatumomab, Inotuzumab Ozogamicin, Hyper-CVAD, Mini-hyper-CVD
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Adverse Effects
- Interventions
- 4% lidocaine gel
- Drug
- Lead sponsor
- Mountain States Tumor and Medical Research Institute
- Other
- Eligibility
- 35 Years and older · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Boise, Idaho
- Conditions
- Advanced Solid Tumors
- Interventions
- MEDI5083 monotherapy, MEID5083 with Durvalumab or Tremelimumab, Medi5083 with Durvalumab and Docetaxel
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 101 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 4
- States / cities
- Hackensack, New Jersey • Providence, Rhode Island • Nashville, Tennessee + 1 more
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
- Interventions
- Hydroxychloroquine, Letrozole, Palbociclib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Diabetic Macular Edema
- Interventions
- Brolucizumab, Aflibercept
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 517 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 74
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 66 more
- Conditions
- Parkinson's Disease Psychosis
- Interventions
- Pimavanserin tartrate (ACP-103), Placebo
- Drug
- Lead sponsor
- ACADIA Pharmaceuticals Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 298 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 36
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Berkeley, California + 33 more
- Conditions
- Hiv, HSV
- Interventions
- TAF/EVG Vaginal Insert
- Drug
- Lead sponsor
- CONRAD
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
- Interventions
- SPY001, SPY002, SPY003, Placebo
- Drug · Other
- Lead sponsor
- Spyre Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 645 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 27
- States / cities
- Canoga Park, California • La Jolla, California • Lancaster, California + 24 more
- Conditions
- Herpes Zoster
- Interventions
- Herpes Zoster Vaccine GSK1437173A, Placebo
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 16,165 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2015
- U.S. locations
- 43
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more
- Conditions
- Psoriasis
- Interventions
- U0267 Foam, Vehicle foam
- Drug
- Lead sponsor
- Stiefel, a GSK Company
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 12
- States / cities
- Mobile, Alabama • Fremont, California • Ormond Beach, Florida + 9 more
- Conditions
- Participants With Moderate and Severe Renal Impairment and Healthy Participants
- Interventions
- PKN605
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • Tampa, Florida
- Conditions
- Facial Papulopustular Rosacea
- Interventions
- FMX103 minocycline foam 1.5%, Vehicle foam
- Drug
- Lead sponsor
- Vyne Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 751 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 54
- States / cities
- Tucson, Arizona • Fremont, California • Los Angeles, California + 46 more
- Conditions
- Gastric Cancer, Colorectal Cancer, Pancreatic Cancer, Biliary Cancer
- Interventions
- AbGn-107
- Biological
- Lead sponsor
- AbGenomics B.V Taiwan Branch
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • San Francisco, California • Boston, Massachusetts + 1 more
- Conditions
- Lymphoma, Solid Tumor
- Interventions
- GDC-0575, Gemcitabine
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 5
- States / cities
- New Haven, Connecticut • Boston, Massachusetts • Detroit, Michigan + 2 more
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
- Interventions
- NS-018
- Drug
- Lead sponsor
- NS Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • San Diego, California • Jacksonville, Florida + 5 more
- Conditions
- Dyslipidemia
- Interventions
- LCP-AtorFen, atorvastatin, fenofibrate
- Drug
- Lead sponsor
- Asahi Kasei Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Multiple System Atrophy
- Interventions
- YA-101, Placebo
- Drug
- Lead sponsor
- Dasher Neuroscience Inc.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 3 more